We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NJ-based medical device manufacturer, Integra LifeSciences Holdings Corporation (IART - Free Report) reported adjusted earnings per share (EPS) of 52 cents in the fourth quarter of 2016, which marked an 18% increase from the year-ago adjusted number.
Adjusted EPS however was in line with the Zacks Consensus Estimate. Including one-time items, the company reported earnings of 35 cents per share, up 75% from the year-ago quarter.
Full-year 2016 earnings per share were $1.76, up 14.3% from the prior year.
Integra LifeSciences Holdings Corporation Price, Consensus and EPS Surprise
Total revenue in the reported quarter increased 6% year over year to $255.7 million. However, the figure missed the Zacks Consensus Estimate of $259 million. Excluding the contribution of revenues from acquisitions, discontinued products and the effect of currency exchange rates, organic revenues rose 7% year over year.
The fourth quarter’s solid revenue growth was primarily driven by strong contribution from both the company’s Specialty Surgical Solutions and Orthopedics and Tissue Technologies segments.
For full-year 2016, Integra LifeSciences’ total revenue rose 12.4% from the year-ago period to $992.1 million.
In terms of product categories, revenues from the company's Specialty Surgical Solutions segment rose 7% (up 7.2% organically) to $163.7 million, aided by strong performance by the dural repair franchise, which grew in high single-digits in the reported quarter.
Orthopedics and Tissue Technologies’ revenues came in at $91.9 million in the fourth quarter, up 4.3% year over year (up 6.6% organically). Regenerative Technologies, the largest franchise in the segment, increased high single-digits in the fourth quarter.
Margin Trends
Gross margin expanded 391 basis points (bps) to 66.5% in the reported quarter. Adjusted gross margin improved 190 bps to 70.2%, reflecting favorable product mix.
Selling, general and administrative expenses increased 2.2% to $112.1 million in the reported quarter, and research and development expenses rose 0.3% to $13.9 million. Adjusted operating margin (excluding amortization of intangible asset) experienced an expansion of 586 bps to 17.3% in the fourth quarter.
Financial Position
Integra LifeSciences exited fiscal 2016 with cash and cash equivalents of $102.0 million, up from $48.1 million recorded in the prior year. Full-year 2016, net cash flow from operating activities was $116.4 million, down from $117.0 million in the year-ago period.
2017 Outlook
Management expects full-year 2017 revenues in the range of $1.12 billion to $1.14 billion, including the Derma Sciences acquisition and organic sales growth between 7% and 8.5%. The Zacks Consensus Estimate for full-year 2017 revenues is at $1.19 billion, which is ahead of the guided range.
The company also projects adjusted EPS between $1.88 and $1.94. The Zacks Consensus Estimate for 2017 adjusted earnings is pegged at $2.21 per share, which is also way above the guided range.
Our Take
Integra Lifesciences reported mixed fourth-quarter results with earnings meeting the Zacks Consensus Estimate and revenues missing the mark. We are concerned about the currency headwind that is expected to considerably affect Integra Lifesciences’ financial performance in 2017. The rise in operating expenses, the integration costs of Derma Sciences and pre-closing costs for Codman Neurosurgery acquisition are likely to affect the company in the upcoming quarters.
Nonetheless, we believe the company will successfully overcome these hurdles soon, backed by new product launches and an efficient management team. During the reported quarter, the company recorded strong year-over-year improvement on the revenue front which is indicative of the company's healthy growth via organic and inorganic means across all segments.
Zacks Rank & Key Picks
Integra Lifesciences currently has a Zacks Rank #3 (Hold). Better-ranked medical stocks are Glaukos Corporation (GKOS - Free Report) , Cardiovascular Systems and Neogen Corp. (NEOG - Free Report) . Glaukos sports a Zacks Rank #1 (Strong Buy) while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos gained over 100% in the last one year in comparison to the S&P 500’s gain of 21.5%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 31.1% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Integra (IART) Posts In-Line Q4 Earnings, Issues 2017 View
NJ-based medical device manufacturer, Integra LifeSciences Holdings Corporation (IART - Free Report) reported adjusted earnings per share (EPS) of 52 cents in the fourth quarter of 2016, which marked an 18% increase from the year-ago adjusted number.
Adjusted EPS however was in line with the Zacks Consensus Estimate. Including one-time items, the company reported earnings of 35 cents per share, up 75% from the year-ago quarter.
Full-year 2016 earnings per share were $1.76, up 14.3% from the prior year.
Integra LifeSciences Holdings Corporation Price, Consensus and EPS Surprise
Integra LifeSciences Holdings Corporation Price, Consensus and EPS Surprise | Integra LifeSciences Holdings Corporation Quote
Revenue Details
Total revenue in the reported quarter increased 6% year over year to $255.7 million. However, the figure missed the Zacks Consensus Estimate of $259 million. Excluding the contribution of revenues from acquisitions, discontinued products and the effect of currency exchange rates, organic revenues rose 7% year over year.
The fourth quarter’s solid revenue growth was primarily driven by strong contribution from both the company’s Specialty Surgical Solutions and Orthopedics and Tissue Technologies segments.
For full-year 2016, Integra LifeSciences’ total revenue rose 12.4% from the year-ago period to $992.1 million.
In terms of product categories, revenues from the company's Specialty Surgical Solutions segment rose 7% (up 7.2% organically) to $163.7 million, aided by strong performance by the dural repair franchise, which grew in high single-digits in the reported quarter.
Orthopedics and Tissue Technologies’ revenues came in at $91.9 million in the fourth quarter, up 4.3% year over year (up 6.6% organically). Regenerative Technologies, the largest franchise in the segment, increased high single-digits in the fourth quarter.
Margin Trends
Gross margin expanded 391 basis points (bps) to 66.5% in the reported quarter. Adjusted gross margin improved 190 bps to 70.2%, reflecting favorable product mix.
Selling, general and administrative expenses increased 2.2% to $112.1 million in the reported quarter, and research and development expenses rose 0.3% to $13.9 million. Adjusted operating margin (excluding amortization of intangible asset) experienced an expansion of 586 bps to 17.3% in the fourth quarter.
Financial Position
Integra LifeSciences exited fiscal 2016 with cash and cash equivalents of $102.0 million, up from $48.1 million recorded in the prior year. Full-year 2016, net cash flow from operating activities was $116.4 million, down from $117.0 million in the year-ago period.
2017 Outlook
Management expects full-year 2017 revenues in the range of $1.12 billion to $1.14 billion, including the Derma Sciences acquisition and organic sales growth between 7% and 8.5%. The Zacks Consensus Estimate for full-year 2017 revenues is at $1.19 billion, which is ahead of the guided range.
The company also projects adjusted EPS between $1.88 and $1.94. The Zacks Consensus Estimate for 2017 adjusted earnings is pegged at $2.21 per share, which is also way above the guided range.
Our Take
Integra Lifesciences reported mixed fourth-quarter results with earnings meeting the Zacks Consensus Estimate and revenues missing the mark. We are concerned about the currency headwind that is expected to considerably affect Integra Lifesciences’ financial performance in 2017. The rise in operating expenses, the integration costs of Derma Sciences and pre-closing costs for Codman Neurosurgery acquisition are likely to affect the company in the upcoming quarters.
Nonetheless, we believe the company will successfully overcome these hurdles soon, backed by new product launches and an efficient management team. During the reported quarter, the company recorded strong year-over-year improvement on the revenue front which is indicative of the company's healthy growth via organic and inorganic means across all segments.
Zacks Rank & Key Picks
Integra Lifesciences currently has a Zacks Rank #3 (Hold). Better-ranked medical stocks are Glaukos Corporation (GKOS - Free Report) , Cardiovascular Systems and Neogen Corp. (NEOG - Free Report) . Glaukos sports a Zacks Rank #1 (Strong Buy) while Cardiovascular Systems and Neogen carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos gained over 100% in the last one year in comparison to the S&P 500’s gain of 21.5%. The company has a stellar four-quarter average earnings surprise of over 100%.
Cardiovascular Systems surged over 100% in the last one year in comparison to the S&P 500. It has a four-quarter average earnings surprise of 67.8%.
Neogen gained 31.1% in the past one year, better than the S&P 500 mark. The stock has an impressive long-term earnings growth rate of 16.7% for the next five years compared to the industry average of 15.2%.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>